(NASDAQ: TARS) Tarsus Pharmaceuticals's forecast annual revenue growth rate of 35.22% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.61%.
Tarsus Pharmaceuticals's revenue in 2025 is $366,100,000.On average, 10 Wall Street analysts forecast TARS's revenue for 2025 to be $19,201,428,156, with the lowest TARS revenue forecast at $18,405,931,928, and the highest TARS revenue forecast at $19,843,258,623. On average, 9 Wall Street analysts forecast TARS's revenue for 2026 to be $29,399,401,141, with the lowest TARS revenue forecast at $25,138,784,472, and the highest TARS revenue forecast at $34,617,245,128.
In 2027, TARS is forecast to generate $38,153,680,065 in revenue, with the lowest revenue forecast at $33,280,098,320 and the highest revenue forecast at $44,614,009,355.